Business Wire

LIDE Biotech Participates in VERIF.i ® , Scientist.com’s Supplier Pre-assessment Program, to Support Continued Growth in North America and the EU

Share

Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i®, the company’s supplier pre-assessment program, has been used to successfully complete an on-site assessment of the LIDE Biotech facility in Shanghai, China. VERIF.i was developed to help users on both sides of the Scientist.com marketplace improve quality standards and reduce indirect costs.

LIDE (Lab for Innovated Diagnosis and Experimental Therapeutics) Biotech is a translational medicine service provider that has delivered innovations in oncology translational research and immune-oncology for the past 11 years. LIDE was founded by overseas returnees Drs. Danyi Wen, Yizhun Zhu and others, with the goal of bringing together first-class research and management teams with advanced scientific backgrounds to push the frontier of translational medical research. LIDE is committed to superior research quality; in 2015, it partnered with several large pharma and biotech companies to create a PDX Consortium Board with the goal of promoting and ensuring high PDX standards across China.

“At LIDE we hold ourselves to the highest industry standards by ensuring superior quality of our facilities and the world class scientists operating them,” stated Dr. Danyi Wen, President and CEO of LIDE Biotech. “Together with other industry certifications, VERIF.i allows us to showcase our quality commitment across the industry in North America and Europe as well as in the growing Scientist.com marketplace.”

VERIF.i gives suppliers of regulated research services the opportunity to proactively communicate their standards against pre-defined criteria developed for the biopharma industry and then confirm them through independent, third-party auditors that carry out an on-site inspection. Pre-assessments help suppliers such as LIDE Biotech demonstrate their quality and capabilities, while also helping pharma and biotech customers purchase regulated services in an accelerated manner with more confidence and less risk.

“Even prior to the Covid-19 pandemic, on-site assessments of laboratories were difficult to complete owing to the high cost and intensive resource and time requirements,” stated Matt McLoughlin, SVP of Categories and Compliance at Scientist.com. “VERIF.i addresses these challenges by creating a standardized process for both customers and suppliers. It also enables suppliers like LIDE to differentiate themselves from their peers by sharing independent insight into their facilities, personnel and processes."

VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/

About LIDE Biotech

LIDE biotech is committed to accelerating translation from pre-clinical to clinical for our clients. We do this through our unique access to fresh patient samples, received daily via our close hospital partnerships across China. These relationships combined with our proprietary kits, tumor sample kit, CRC kit, MiniPDX assay kit, and K-Cell kits, LIDE’s platform gives our clients the competitive edge to save time and budget. Based on this success, LIDE has built a robust database of over 1600+ PDX, CDX, and Cell Line models which grows daily. Our CRO services can be custom tailored based on what stage of the pre-clinical oncology drug development process you’re in, including clinical biopsy collection, in vitro/in vivo studies, transcription RNA and DNA analysis, and Immuno-Oncology capabilities.

LIDE Biotech will be at the American Association for Cancer Research Annual Meeting in New Orleans from April 10 – 13. Stop by First Floor Exhibit Hall D-H, Booth # 2057.

Watch LIDE Biotech’s Director of Immuno-Oncology, Dr. Bin Xie discuss current and novel Immuno-Oncology drug evaluation methods via humanized mouse models on a Scientist.com-hosted webinar.

Visit www.lidebiotech.com to learn more and follow updates on the LIDE Biotech LinkedIn page.

About Scientist.com

Scientist.com’s mission is to empower and connect scientists worldwide. By transforming the way scientific research is performed, our Science as a Service® platform accelerates discoveries that prevent and cure disease, address climate change and help secure global food and energy supplies. We combine sophisticated AI technology with white-glove Research Concierge® support to enable scientists to run more innovative experiments in less time and at lower cost.

Visit scientist.com to learn more.

Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sean Preci
+1 858 455-1300 ext. 401
marketing@scientist.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

QCT Delivers on the 5G Promise with Innovative Edge Infrastructures and 5G Solutions16.5.2022 13:00:00 CEST | Press release

Quanta Cloud Technology (QCT), a leading data center hardware solution provider, today announced details around its participation at the Big 5G Event 2022, being held onsite from May 16 – May 18, at the Austin Convention Center in Austin, Texas. QCT will showcase 5G infrastructure and solution demos at Booth #300 for both public and private networks and share their latest insights at the event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220516005006/en/ (Graphic: Business Wire) To support the ever-growing compute and networking needs at the telco edge, QCT showcases its latest QuantaEdge products and solutions powered by Intel Xeon-SP and Xeon-D processors, spanning carrier grade 5G systems, edge servers and radio units that are cloud native to deliver maximum deployment flexibility. QCT demo highlights include: QuantaEdge EGD33B-WT - a next-gen outdoor pole-mount edge server designed for vRAN/MEC use cases, featuring a

Solynta and Incotec Announce Partnership to Optimize Performance of Hybrid True Potato Seeds16.5.2022 12:00:00 CEST | Press release

Hybrid potato innovator Solynta and seed enhancement company Incotec have entered in a collaboration agreement. By combining forces, the group will bring world-class seed technology and elite genetics to potato farmers worldwide. Solynta is a Netherlands-based company using hybrid potato breeding to grow a more sustainable future. Solynta has developed a unique portfolio of hybrid potato varieties for farmers that are dependable, productive and resilient to climate change. Incotec, a global seed enhancement company, has developed technologies including a new pelletization method and seed priming formula specifically tailored for true potato seeds. This seed technology will allow Solynta’s true potato seeds to succeed in diverse growing environments. Johan Trouw, Solynta Supply Chain Director and co-founder, noted, “At Solynta, we believe that partnering with industry leaders like Incotec supports our mission of creating solutions for food and nutritional insecurity. Their expertise in

LIVALL Introduces the World's First Detachable Open Ear Headphones16.5.2022 10:43:00 CEST | Press release

Award-winning smart helmet company, LIVALL, is pleased to announce the upcoming launch of the World’s First Detachable Open Ear TWS Headphones. Titled “LTS21”, the headphones can be used by anybody who wants comfortable headphones. To learn more about LTS21, please visit: https://www.youtube.com/watch?v=P505tZljrb0 LIVALL prides itself in being a company that listens to customers’ needs and expectations, and the very ethos has been the foundation of the development of LTS21. Per the statements of LIVALL founder, the innovative LTS21 has been uniquely designed to ensure unparalleled comfort, performance, and convenience for users. “We are developing a cutting-edge technology accessory to match perfectly with helmets. Our team is working diligently to stay ahead in our latest innovations and offer quality products and surprises. Our latest Indiegogo campaign will allow us to provide early pricing to all of our backers. We are excited to bring our latest product and the World's First Deta

Early-Stage Investments for Turkish Metaverse Platform MetaAge Nears $1-Million Mark16.5.2022 10:00:00 CEST | Press release

MetaAge, a metaverse platform based on the Solana Blockchain, has drawn almost $1 million in early-stage investments, project managers said this week. Currently, under development in Turkey, the platform has just entered its alpha phase, during which it plans to work closely with 50 global NFT projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005497/en/ MetaAge is an augmented-reality platform where users can do practically everything they do in real life – from socializing and playing games to buying property and generating revenue. (Graphic: Business Wire) “We plan to expand globally within a relatively short period of time,” Mustafa Ekinci, MetaAge creator and co-founder, says. “The platform has already generated significant international interest,” he adds, noting that its rapidly growing Discord community now includes more than 10,000 people from all over the world, while it also got 4000 people whitelisted

Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program16.5.2022 09:30:00 CEST | Press release

Celmatix Inc. a biotechnology company focused on ovarian biology, today announced the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug. The program, which was a product of Celmatix’s decade-long focus on identifying novel biomarkers and drug targets for women’s health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy. Loss of ovarian function and menopause are accelerated by approximately 1.5 years for each month a woman receives chemotherapy treatment. “Demographically speaking, menopause is a relatively new phenomenon and is the result of medical breakthroughs that allow women to now routinely outlive their ovarian function” remarked Dr. Piraye Yurttas Beim, Celmatix founder and CEO. “A century ago, the average life expec